Oncology Models | Charles River Discovery Services

Cachexia Model 

The Yoshida ascites hepatoma model induces cachexia and produces tissue wasting, particularly in skeletal muscle. This very aggressive, short-term model is used to evaluate the anti-cachectic effects of a therapy. With therapies typically beginning on the first day and continuing to the end of the study, heart, gastrocnemius and ascites are measured at sacrifice and used to evaluate efficacy of the therapy.

For more information about our cachexia model, please contact us at 1.877.CRIVER.1 or askcharlesriver@crl.com.

Discover the full range of Charles River Products and Services
The Source

For more information, contact us at:

1.877.CRIVER.1 (1.877.274.8371)
askcharlesriver@crl.com

view all

News & Events

view all
May 14 - New Models for Evaluating COPD or ...
May 11 - Expert Safety Testing to Accelerat...
Jun 17-Jun 20 -  Noordwijk aan Zee, the Netherlands - 19th MDO Meeting / 12th European ...
Jun 02-Jun 05 - Vancouver, British Columbia - CALAS
Jun 05-Jun 05 - King of Prussia, Pennsylvania - Assessment of Immunomodulation for Biol...
Jun 05-Jun 08 - Saint Germain sur l’Arbresle, France - Charles River LAL Seminar Series
view all
Scientist I Wilmington, MA
Manager International Tax Wilmington, MA

Charles River Laboratories, Inc.